| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 1.3 | 1.4 |
| Gross profit | 0.1 | 0.4 |
| Profit before tax | -1.2 | 0.0 |
| Net income | -1.2 | 0.0 |
| EPS (diluted, $ a share) | $-0.37 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -8.3% |
|---|---|
| Gross margin | 8.1% |
| Operating margin | -97.0% |
10-Q filed with the SEC, NASDAQ: BMRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biomerica Inc: key numbers
- Share price
- $1.24Close, Nov 17
- Market cap
- $5.68M
- Shares outstanding
- 4.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biomerica Inc
All →Biomerica Leadership Change
David Moatazedi, a member of the Board of Directors and Chairperson of the Compensation Committee, has determined not to stand for re-election at the company's 2026 Annual Meeting of Stockholders. His departure, effective December 11, 2026, is not due to any dispute or disagreement with the company. Mr. Moatazedi has served on the Biomerica board since December 2022.